<DOC>
	<DOCNO>NCT00299351</DOCNO>
	<brief_summary>To evaluate safety tolerability extend treatment depsipeptide patient least demonstrated stable disease prior Gloucester-sponsored depsipeptide clinical trial , opinion physician/ investigator might benefit continued treatment depsipeptide</brief_summary>
	<brief_title>A Multicenter , Open-Label Continuation Trial Evaluating Tolerability Activity Depsipeptide ( FK228 ) Patients That Have Completed Prior Clinical Study With Depsipeptide .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Written inform consent/ authorization Patient complete 6 cycle therapy prior Gloucestersponsored depsipeptide clinical trial Patient immediate past participation ( exceed 21 day Day 15 cycle 6 previous study ) prior Gloucestersponsored depsipeptide clinical trial Patient demonstrate stable disease , partial response complete response best overall response prior Gloucestersponsored depsipeptide clinical trial response must ongoing time enrollment Patient must serum potassium level &gt; 4.0mEq/L serum magnesium level &gt; 2.0mg/dL Negative urine serum pregnancy test female childbearing potential Sexually active female childbearing potential must willing practice reliable method birth control prevent pregnancy enter trial Sexually active male must willing practice reliable method birht control enter trial Patients wiht know cardiac abnormality congenital long QT syndrome QTc interval &gt; 480 millisecond Patients cardiac arrhythmia require antiarrhythmic medication Patients history coronary artery disease ( CAD ) eg . angina Canadian class IIIV ( see appendix G ) &gt; In patient doubt , patient stress image study , abnormal , angiopathy define whether CAD present Patients myocardial infarction within 12 month study entry . Patients ECG record screen show evidence cardiac ishemia ( ST depression &gt; 2mm ) . If doubt , patient stress image study abnormal , angiograpphy define whether CAD present Patients congestive heart failure meet New York heart Association ( NYHA ) Class II IV ( see appendix F ) definition and/or ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram and/or magnetic resonance imaging ( MRI ) Patients history sustain VT , VF , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) Patients hypertrophic cardiomelagy restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) Patients uncontrolled hypertension ie &gt; 160/95 Concomitant use medication may cause prolongation QT/QTc Concomitant use medication inhibitor cytochrome P450 isoenzyme CYP 3A4 Absolute neutrophil count ( ANC ) &lt; 1.5 X 109 cells/L Platelet count &lt; 75 x 109 cells/L Serum creatinine concentration &gt; 2 mg/dL creatinine clearance &lt; 40mL/min AST ( aspartate aminotransferase ) alanine aminotransferase ( ALT ) &gt; 2.0 x ULN &gt; 5 X ULN presence demonstable liver metastasis Bilirubin concentration &gt; 1.25 x ULN &gt; 2.0 x ULN presence demonstrable liver metastasis Serum potassium &lt; 4.0mEq/L serum magnesium &lt; 2.0 mg/dL Failure recover drugrelated nonhematological toxicity grade 1 oe less baseline value unless otherwise indicate Concomitant use warfarin ( due potentialdrug drug interaction depsipeptide ) Patient pregnant nursing Patient prior Gloucestersponsored depsipeptide clinical trial , leave trial receive alternative neoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>